Prodrug-activating gene therapy with rabbit cytochrome P450 4B1/4-ipomeanol or 2-aminoanthracene system in glioma cells

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 3, 2010, Pages 193-198

  Jang, Su Jin ^a   Kang, Joo Hyun ^a   Lee, Tae Sup ^a   Kim, Sung Joo ^a   Kim, Kwang Il ^a   Lee, Yong Jin ^a   Cheon, Gi Jeong ^a   Choi, Chang Woon ^a   Lim, Sang Moo ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Cytochrome P450 4B1; Firefly luciferase; Glioma; Prodrug activating gene therapy

Indexed keywords

2 AMINOANTHRACENE; 4 IPOMEANOL; COMPLEMENTARY DNA; CYTOCHROME P450 4B1; FIREFLY LUCIFERASE; PRODRUG;

ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE DIRECTED ENZYME PRODRUG THERAPY; GLIOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 79952736972     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-010-0038-8     Document Type: Article

References (18)

1. Springer CJ, Niculescu-Duvaz I. (2000) Prodrug-activating systems in suicide gene therapy. J Clin Invest 105:1161-1167.
2. Sasaki M, Plate KH. (1998) Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Ann Oncol 9:1155-1156.
3. Moolten FL. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276-5281.
4. Li Z, Shanmugam N, Katayose D, Huber B, Srivastava S, Cowan K. et al. (1997) Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 4:113-117.
5. Parker WB, King SA, Allan PW, Bennett LL, Secrist JA, Montgomery JA. et al. (1997) In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther 8:1637-1644.
6. Denny WA. (2003) Prodrugs for gene-directed enzyme-prodrug therapy. (suicide gene therapy). J Biomed Biotechnol 1:48-70.
7. 1/2 cells expressing rabbit cytochrome. Biochem Pharmacol 50:1567-1575.
8. Dahl AR, Lewis JL. (1993) Respiratory tract uptake of inhalants and metabolism of xenobiotics. Annu Rev Pharmacol Toxicol 32:383-407.
9. Baer BR, Rettie AE. (2006) CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism. Drug Metab Rev 38:451-476.
10. Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM. et al. (1998) New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther 9:1261-1273.
11. Rainov NG, Sena-Esteves M, Fraefel C, Dobberstein KU, Chiocca EA, Breakefield XO. (1998) A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein fordetection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv Exp Med Biol 451:393-403.
12. Kasturi VK, Dearing MP, Piscitelli SC, Russell EK, Sladek GG, O'Neil K. et al. (1998) Phase I study of a five-day dose schedule of 4-ipomeanol in patients with non-small cell lung cancer. Clin Cancer Res 1998;4:2098-2102.
13. Rowinsky EK, Noe DA, Ettinger DS, Christian MC, Lubejko BG, Fishman EK. et al. (1993) Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res 53:1794-1801.
14. Mohr L, Rainov NG, Mohr UG, Wands JR. (2000) Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma. Cancer Gene Ther 7:1008-1014.
15. Hsu H, Rainov NG, Quinones A, Elinq DJ, Sakamoto KM, Spear MA. (2003) Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Res 23:2723-2728.
16. Steffens S, Frank S, Fischer U, Heuser C, Meyer KL, Dobberstein KU. et al. (2000) Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy. Cancer Gene Ther 7:806-812.
17. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. (1983) A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 43:749-757.
18. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth 65:55-63.